Ricardo Vallejo's guest appearances

Ricardo Vallejo

López-Dóriga

Spine & Nerve podcast

Kamala Harris

Donald Trump

David Shields

Kevin Mullins

Michael Fishman

Max Scherzer

Klay Thompson

Luis Rojas

Eduardo Ojeda

Erich Anderer

MARIO ROMERO

Krystyna Holland

Ee I

Daniel Zovatto

Laura Garza

OwlTail

Este mes termina la primera etapa del Aeropuerto y termina la segunda etapa a partir del 1 de marzo

Es un compromiso, que el 21 de marzo de 2022, Aeropuerto de Santa Lucía esté inaugurado: Ricardo Vallejo 

El General Ingeniero señaló que en Santa Lucía, 450 mil metros cuadrados de instalaciones militares están siendo reasignadas

En febrero estará lista la pista militar del nuevo aeropuerto: Ricardo Vallejo 

This week's episode of the Spine &amp; Nerve podcast is a very special episode. Dr. Nicolas Karvelas and Dr. Brian Joves had the opportunity to speak with one of the leaders in the field of pain medicine and pain research, Dr. Ricardo Vallejo.Dr. Vallejo is the co-founder and director of research at Millennium Pain Center in Bloomington, Illinois, and founder and lead investigator of Stimgenics, LLC. They have pioneered a novel spinal cord stimulation (SCS) waveform known as Differential Target Multiplexed (DTM) Spinal Cord Stimulation. Stimgenics’ preclinical research on the neuronal-glial mechanism of action has been recognized at various medical society meetings, receiving six “best of” awards for their research, three of which were specific to research investigating the DTM mechanism of action. NANS awarded the “Best Basic Science Research Award” to Stimgenics at their annual meeting in both 2018 and 2019.In this discussion, the docs dive deep into:- glial cells and their role in chronic pain.- What exactly is DTM?- How is the basic science translating into clinical outcomes?- What do we, as a field/specialty, have to do to continue to progress and change things for our patients?There were many studies referenced in this discussion, here is a short list of the most relevant literature:1. Fishman M, Cordner H, Justiz R, et al. Randomized Controlled Clinical Trial to Study the Effects of SGX-SCS in Treating Intractable Chronic Low Back Pain: 3 Month Results. North American Neuromodulation Society (NANS); 2020; Las Vegas, Nevada.2. Calodney AK, Kim PS, Slezak J, et al. Prospective study evaluating differential-target- multiplexed SCS for chronic intractable back pain with or without leg pain. Neuromodulation: Technology at the Neural Interface. 2019;22(3):e40-e295.3. Fishman M, Calodney A, Kim P, et al. Prospective, multicenter trial to evaluate Multiplexed SCS for differential targets in subjects with chronic intractable back pain with or without leg pain. North American Neuromodulation Society (NANS); 2019; Las Vegas, NV.4. Cedeno DL, Cass CL, Kelley CA, et al. Pre-clinical comparison of differential-target multiplexed scstm with low and high rate SCS. Neuromodulation: Technology at the Neural Interface. 2019;22(3):e40-e295.5. Vallejo R, Kelley C, Smith W, Tilley D, Cedeno D. Cell-specific targeting in neural tissue using Differential Target Multiplexed (DTM) SCS. American Society of Regional Anesthesiology and Pain Medicine (ASRA); 2019; New Orleans, LA.6. Vallejo R, Kelley CA, Smith WJ, Tilley DM, Cedeno D. Targeting specific cell populations in neural tissue with DTM-SCS. North American Neuormodulation Society (NANS); 2020; Las Vegas, NV.7. Vallejo R, Smith W, Kelley C, Tilley D, Cedeno D. Neuron-glial inflammasome enhanced reversal by DTM-SCS relative to high rat and low rate SCS in a neuropathic pain model. American Society of Regional Anesthesiology and Pain Medicine (ASRA); 2019; New Orleans, LA.8. Cedeno D, Smith WJ, Kelley CA, Tilley DM, Sanapati S, Vallejo R. DTM-SCS enhances reversal of neuron-glial inflammasome relative to high rate and low rate. North American Neuromodulation Society (NANS); 2020; Las Vegas, NV.9. Vallejo R, Tilley D, Kelley C, Smith W, Cedeno D. Proteomics of Differential Target Muliplexed- SCS applied to an animal model of neuropathic pain. American Society of Regional Anesthesiologists and Pain Medicine (ASRA); 2019; New Orleans, LA.10. Vallejo R, Kelley CA, Smith WJ, Tilley DM, Cedeno D. Proteomics of differential target multiplexed-SCS applied to an animal model of neuropathic pain. North American Neuromodulation Society 2020; Las Vegas, NV. This podcast is for information and educational purposes only, it is not meant to be medical advice. If anything discussed may pertain to you, please seek council with your healthcare provider. The views expressed are those of the individuals expressing them, they may not represent the views of Spine &amp; Nerve.

This week's episode of the Spine &amp; Nerve podcast is a very special episode. Dr. Nicolas Karvelas and Dr. Brian Joves had the opportunity to speak with one of the leaders in the field of pain medicine and pain research, Dr. Ricardo Vallejo. Dr. Vallejo is the co-founder and director of research at Millennium Pain Center in Bloomington, Illinois, and founder and lead investigator of Stimgenics, LLC. They have pioneered a novel spinal cord stimulation (SCS) waveform known as Differential Target Multiplexed (DTM) Spinal Cord Stimulation. Stimgenics’ preclinical research on the neuronal-glial mechanism of action has been recognized at various medical society meetings, receiving six “best of” awards for their research, three of which were specific to research investigating the DTM mechanism of action. NANS awarded the “Best Basic Science Research Award” to Stimgenics at their annual meeting in both 2018 and 2019. In this discussion, the docs dive deep into: - glial cells and their role in chronic pain. - What exactly is DTM? - How is the basic science translating into clinical outcomes? - What do we, as a field/specialty, have to do to continue to progress and change things for our patients? There were many studies referenced in this discussion, here is a short list of the most relevant literature: 1. Fishman M, Cordner H, Justiz R, et al. Randomized Controlled Clinical Trial to Study the Effects of SGX-SCS in Treating Intractable Chronic Low Back Pain: 3 Month Results. North American Neuromodulation Society (NANS); 2020; Las Vegas, Nevada. 2. Calodney AK, Kim PS, Slezak J, et al. Prospective study evaluating differential-target- multiplexed SCS for chronic intractable back pain with or without leg pain. Neuromodulation: Technology at the Neural Interface. 2019;22(3):e40-e295. 3. Fishman M, Calodney A, Kim P, et al. Prospective, multicenter trial to evaluate Multiplexed SCS for differential targets in subjects with chronic intractable back pain with or without leg pain. North American Neuromodulation Society (NANS); 2019; Las Vegas, NV. 4. Cedeno DL, Cass CL, Kelley CA, et al. Pre-clinical comparison of differential-target multiplexed scstm with low and high rate SCS. Neuromodulation: Technology at the Neural Interface. 2019;22(3):e40-e295. 5. Vallejo R, Kelley C, Smith W, Tilley D, Cedeno D. Cell-specific targeting in neural tissue using Differential Target Multiplexed (DTM) SCS. American Society of Regional Anesthesiology and Pain Medicine (ASRA); 2019; New Orleans, LA. 6. Vallejo R, Kelley CA, Smith WJ, Tilley DM, Cedeno D. Targeting specific cell populations in neural tissue with DTM-SCS. North American Neuormodulation Society (NANS); 2020; Las Vegas, NV. 7. Vallejo R, Smith W, Kelley C, Tilley D, Cedeno D. Neuron-glial inflammasome enhanced reversal by DTM-SCS relative to high rat and low rate SCS in a neuropathic pain model. American Society of Regional Anesthesiology and Pain Medicine (ASRA); 2019; New Orleans, LA. 8. Cedeno D, Smith WJ, Kelley CA, Tilley DM, Sanapati S, Vallejo R. DTM-SCS enhances reversal of neuron-glial inflammasome relative to high rate and low rate. North American Neuromodulation Society (NANS); 2020; Las Vegas, NV. 9. Vallejo R, Tilley D, Kelley C, Smith W, Cedeno D. Proteomics of Differential Target Muliplexed- SCS applied to an animal model of neuropathic pain. American Society of Regional Anesthesiologists and Pain Medicine (ASRA); 2019; New Orleans, LA. 10. Vallejo R, Kelley CA, Smith WJ, Tilley DM, Cedeno D. Proteomics of differential target multiplexed-SCS applied to an animal model of neuropathic pain. North American Neuromodulation Society 2020; Las Vegas, NV. This podcast is for information and educational purposes only, it is not meant to be medical advice. If anything discussed may pertain to you, please seek council with your healthcare provider. The views expressed are those of the individuals expressing them, they may not represent the views of Spine &amp; Nerve.

More glial cells!! Dr. Ricardo Vallejo, science that matters, and thinking beyond the neuron.